Although it is not a transcription factor, it is important to include CYP2E1, which becomes activated following insulin resistance and lipotoxicity [152] and promotes ROS production in the setting of NAFLD [153]. Here, CYP2E1 is linked to metabolic dysfunction-associated steatotic liver disease.